Is NCT05996627 recruiting in Boston, MA?

Yes, NCT05996627 is currently recruiting participants at its Boston, MA location. This chronic graft versus host disease clinical trial is actively enrolling qualified participants.

How do I join the chronic graft versus host disease clinical trial in Boston?

To join this clinical trial in Boston, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Boston clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Chronic Graft Versus Host Disease Clinical Trial in Boston, MA

About This Chronic Graft Versus Host Disease Study in Boston

This phase II trial compares the effect of belumosudil to a placebo in treating patients with chronic graft versus host disease. Chronic graft versus host disease remains a major complication of stem cell transplantation and can involve multiple organ systems. Belumosudil is a ROCK2 selective inhibitor that works to reduce the immune system response causing the chronic graft versus host disease. Giving belumosudil may better treat patients with chronic graft versus host disease and prevent the n

Sponsor: Fred Hutchinson Cancer Center

Who Can Participate

Inclusion Criteria

At least one diagnostic or distinctive cGVHD manifestation(s), with a clinical diagnosis of cGVHD,but patients do not need to meet National Institute of Health (NIH) criteria for cGVHD

If eye involvement only, cGVHD must be confirmed on exam by an ophthalmologist or optometrist

No new immune suppressive therapy added within preceding 2 weeks prior to study enrollment for any indication

Continuation of agents previously given as either GVHD prophylaxis or acute/late acute GVHD therapy are permitted. Modification of dose of these agents for targeting of therapeutic drug levels is permitted, as are decreases in existing prednisone or prednisone equivalent dose based on routine clinical tapering practices. Increases in prednisone or prednisone equivalents are not allowed in the 2 weeks prior to enrollment

Age 18 and older

Karnofsky performance score \>= 70

Able to take oral medications

Signed informed consent

Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< 3 x upper limit of normal (ULN)

Total bilirubin =\< 1.5 x ULN, unless due to Gilbert's disease

Glomerular filtration rate (estimated glomerular filtration rate \[eGFR\]) \>= 30 mL/min/1.73 m\^2

Female subjects of childbearing potential have a negative serum or urine pregnancy test at screening. Females of childbearing potential are defined as sexually mature females without prior hysterectomy or who have had any evidence of menses in the past 12 months. However, females who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, anti-estrogens, or ovarian suppression

Sexually active females of childbearing potential enrolled in the study must agree to use two forms of accepted methods of contraception during the course of the study and for 3 months after their last dose of study drug. Effective birth control includes:

Intrauterine device (IUD) plus one barrier method

Stable doses of hormonal contraception for at least 3 months (eg, oral, injectable, implant, transdermal) plus one barrier method

2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gel that contain a chemical to kill sperm)

Surgical sterilization (tubal ligation)

A vasectomized partner

For male subjects who are sexually active and who are partners of females of childbearing potential: Agreement to use two forms of contraception as per above and to not donate sperm during the treatment period and for at least 3 months after the last dose of study drug

No evidence of active malignancy

Exclusion Criteria

Any systemic immune suppressive treatment for cGVHD (topical or local therapies are allowed)

Plan to start systemic immune suppressive therapy for cGVHD or increase steroid dose within 14 days after planned start of study medication

25 mg/kg/day or higher prednisone or prednisone equivalent dose at time of screening

History of non-compliance that in the investigator's opinion would interfere with study participation

Uncontrolled psychiatric illness

Female subject who is pregnant or breast feeding

Previous therapy with belumosudil

Known allergy/sensitivity to belumosudil or any other ROCK2 inhibitor

Treatment with another investigational agent within 28 days (or 5 half-lives, whichever is greater) of enrollment

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT05996627) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Chronic Graft Versus Host Disease Treatment Options in Boston, MA

If you're searching for chronic graft versus host disease treatment options in Boston, MA, this clinical trial (NCT05996627) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced chronic graft versus host disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all chronic graft versus host disease clinical trials near you to find additional studies recruiting in your area.

Chronic Graft Versus Host Disease Clinical Trial in Boston, MA

Expert Care in Boston

IRB Approved

No-Cost Care

Apply for This Boston Location

Why Participate?

Simple Process